GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » Beneish M-Score

Innovative MedTech (Innovative MedTech) Beneish M-Score : -4.60 (As of May. 15, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.6 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Innovative MedTech's Beneish M-Score or its related term are showing as below:

IMTH' s Beneish M-Score Range Over the Past 10 Years
Min: -24.78   Med: -18.89   Max: -4.6
Current: -4.6

During the past 13 years, the highest Beneish M-Score of Innovative MedTech was -4.60. The lowest was -24.78. And the median was -18.89.


Innovative MedTech Beneish M-Score Historical Data

The historical data trend for Innovative MedTech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative MedTech Beneish M-Score Chart

Innovative MedTech Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -18.89 -6.03

Innovative MedTech Quarterly Data
Oct13 Jan14 Apr14 Jul14 Oct14 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.72 -24.78 -6.03 -5.18 -4.60

Competitive Comparison of Innovative MedTech's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Innovative MedTech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative MedTech's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's Beneish M-Score falls into.



Innovative MedTech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Innovative MedTech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.76+0.528 * 1+0.404 * 1.0339+0.892 * 1.2605+0.115 * 0.3378
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0992+4.679 * -0.493764-0.327 * 0.7256
=-4.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.21 Mil.
Revenue was 0.433 + 0.481 + 0.443 + 0.477 = $1.83 Mil.
Gross Profit was 0.433 + 0.481 + 0.443 + 0.477 = $1.83 Mil.
Total Current Assets was $0.30 Mil.
Total Assets was $4.33 Mil.
Property, Plant and Equipment(Net PPE) was $0.71 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.10 Mil.
Selling, General, & Admin. Expense(SGA) was $2.37 Mil.
Total Current Liabilities was $3.80 Mil.
Long-Term Debt & Capital Lease Obligation was $0.67 Mil.
Net Income was -0.188 + -0.165 + -0.871 + -0.8 = $-2.02 Mil.
Non Operating Income was 0.023 + 0.029 + 0.01 + 0.159 = $0.22 Mil.
Cash Flow from Operations was -0.134 + -0.035 + -0.006 + 0.068 = $-0.11 Mil.
Total Receivables was $0.21 Mil.
Revenue was 0.42 + 0.384 + 0.359 + 0.292 = $1.46 Mil.
Gross Profit was 0.42 + 0.384 + 0.359 + 0.292 = $1.46 Mil.
Total Current Assets was $0.33 Mil.
Total Assets was $4.50 Mil.
Property, Plant and Equipment(Net PPE) was $0.84 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.04 Mil.
Selling, General, & Admin. Expense(SGA) was $18.91 Mil.
Total Current Liabilities was $5.59 Mil.
Long-Term Debt & Capital Lease Obligation was $0.81 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.205 / 1.834) / (0.214 / 1.455)
=0.111778 / 0.147079
=0.76

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.455 / 1.455) / (1.834 / 1.834)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.298 + 0.713) / 4.33) / (1 - (0.326 + 0.838) / 4.501)
=0.766513 / 0.741391
=1.0339

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.834 / 1.455
=1.2605

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.036 / (0.036 + 0.838)) / (0.099 / (0.099 + 0.713))
=0.04119 / 0.121921
=0.3378

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.366 / 1.834) / (18.914 / 1.455)
=1.290076 / 12.999313
=0.0992

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.668 + 3.8) / 4.33) / ((0.813 + 5.588) / 4.501)
=1.031871 / 1.422128
=0.7256

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2.024 - 0.221 - -0.107) / 4.33
=-0.493764

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Innovative MedTech has a M-score of -4.60 suggests that the company is unlikely to be a manipulator.


Innovative MedTech Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative MedTech (Innovative MedTech) Business Description

Traded in Other Exchanges
N/A
Address
2310 York Street, Suite 200, Blue Island, IL, USA, 60406
Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: the RX Vitality digital wallet and health care app.
Executives
Merle Griff officer: Chief Executive Officer 2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner 10 percent owner 70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt director, 10 percent owner, other: Chairman of the Board 2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman 10 percent owner 280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts 10 percent owner 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman director, 10 percent owner, officer: President & CEO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc. 10 percent owner 881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine director, officer: CFO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari director, officer: COO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz director 280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo director, officer: President 3163 KENNEDY BLVD, JERSEY CITY NJ 07306

Innovative MedTech (Innovative MedTech) Headlines